Real-World Clinical and Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma treated With Commercial CAR-T Therapy
To date, little is known about the real-world clinical outcomes or PROs among Relapsed/Refractory Multiple Myeloma patients treated with SOC ide-cel and cilta-cel. This study will address this important gap in knowledge
Aim 1: Describe real-world clinical outcomes (i.e., treatment response rates, incidence and severity of immune-mediated toxicities, progression-free and overall survival) among RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy.
Aim 2: Describe real-world PROs (i.e., HRQOL, symptom burden) among RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy.
Aim 3: Explore differences in clinical outcomes and PROs between RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub